Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nirsevimab - MedImmune

Drug Profile

Nirsevimab - MedImmune

Alternative Names: Anti-RSV mAb D25; Anti-RSV MAb-YTE; MEDI-8897; Respiratory syncytial virus monoclonal antibody D25; SP 0232

Latest Information Update: 16 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AIMM Therapeutics
  • Developer MedImmune
  • Class Antivirals; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Respiratory syncytial virus infections

Most Recent Events

  • 30 Jul 2019 Phase-II/III clinical trials in Respiratory syncytial virus infections (In infants, In neonates, Prevention) in Belgium (IM) (NCT03959488)
  • 30 Jul 2019 MedImmune initiates the phase II/III MEDLEY trial in Respiratory syncytial virus infections (In infants, In neonates, Prevention) in Finland, Japan and Estonia (IM) (NCT03959488) (EudraCT2019-000201-69)
  • 23 Jul 2019 Phase-III clinical trials in Respiratory syncytial virus infections (In infants, In neonates, Prevention) in Japan, Estonia, Finland (IM) (NCT03979313) (EudraCT2019-000114-11)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top